Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation
Poster
Moody AT, Tess DA, Li Z, Bulawa C, Fleming J, Maurer TS August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Relationship of Tafamidis Binding-Site Occupancy, Transthyretin Stabilization, and Disease Modification in Tafamidis-Treated Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation
Poster
Gonzalez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia Pavia P, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

A Descriptive Analysis of Patients With ATTR Amyloidosis and a Mixed Phenotype From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Oral Presentation
Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

View Presentation
Poster
Waddington Cruz M, Planté-Bordeneuve V, Inamo J, Kristen A, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile107Val Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Poster
Diemberger I, Lino Cirami C, Luigetti M, Dispenzieri A, Grogan M, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile68Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Poster
Luigetti M, DiPaolantonio A, Mazzeo A, Diemberger I, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Phe64Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Poster
Planté-Bordeneuve V, Dori A, Dispenzieri A, Grogan M, Adams D, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ser77Tyr Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Poster
Grogan M, Sultan MB, Gundapaneni B, Crespo-Leiro MG September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Descriptive Analysis of Women With Transthyretin Amyloid Cardiomyopathy: Examining the Demographics of a Growing Patient Population

View Presentation
Poster
Gonzalez Duarte A, Sultan M, Glass O, Chapman D, Amass L, Mazzeo A September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Effect of Tafamidis on Disease Progression in Patients With Non-Val30Met Transthyretin Amyloid Polyneuropathy: A Sub-Study of the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation